Sounds like the new FDA draft guidance for Individualized Human Genome Editing Products was essentially written for $BEAM & $PRME. youtube.com/watch?v=8UnKO56n…
Glad to be at the @RareDiseases Summit for some Breaking News.This morning I attended the Rare Disease Regulatory Roundtable, moderated by @ComstockRi54463 Assoc. Director of the FDA rare disease hub. Guest speaker #karimMikhail made an announcement about individual gene therapy. He is Director of CBER. Watch it here! Very exciting! @FDA @DCOfficial #science #innovation
This is great news for $PRME as well.
$BEAM
"I think if there is a general just kind of comment that I have that I think these LNPs are really doing quite well. This is a great delivery modality where we are talking about temporary headache, fever, flush kinds of infusion reactions or lab abnormalities in return for a one-time dose that gets you potentially transformative durable efficacy like we are seeing here. It is a pretty good delivery vehicle. We are quite happy with it."
—John Evans, CEO, this morning throwing shade at analysts who are obsessed with the transient side effects of LNPs at dosing vs the permanent effect of the therapy: being cured of their genetic disease.
We just learned that the $PRME volume spike between Oct. 6th & Oct. 9th was not short covering. Short interest as of Oct. 15th was still sitting at 32.8M shares.
Increased my $PRME position to 300K shares. This is one hill I'm willing to die on!
Guess what you can have: $GTLB.
Anthropic built its own git replacement for AI-scale coding. But you can’t have it. thenewstack.io/anthropic-sci…
Many people are saying. $GTLB
Replying to @JasonDClinton
Airgapped, self-managed infrastructure, automatic vulnerability remediation. $GTLB has everything it needs to dominate this next era
Six Seven meme bottom. The hedge is hedging. $TLT.
$PRME all fun and games until we get a proper break out...
I'm increasingly coming to think that @sytses might kickstarted an era of medical agency that's going to test & stun both patients, doctors & regulators alike...
Sometimes things are complicated, sometimes they are not. $PRME
$prme $mrna imo you don't have the VP of Modern Rare Diseases and about 20 employees working on prime lnp editing without there being some smoke here. Moderna market cap alone is up around 7 primes. They know prime is third generation and they killed off their prior editing partnership biospace.com/moderna-walks-a…
I'm delighted to learn that a sitting member of $PRME board of directors (its largest early investor, too) is a fellow short-squeeze enjoyer of left-for-dead yet revolutionary biotech platform companies. Fortunate, really, that the gods keep them in such generous supply these days.🙃

























